文献速递前列腺癌

根治性前列腺切除术中切缘评估策略的成本效益分析

The cost-effectiveness of intraoperative margin assessment strategies during radical prostatectomy.
PubMed 文献 · BJU Int · 2026-01-22

该研究用决策分析模型评估根治性前列腺切除术中NeuroSAFE与共聚焦激光显微镜(CLM)相比双侧、单侧及非神经保留手术的成本效益,以QALY为结局、€50 000/QALY为阈值。结果显示两者相比非术中评估策略均具成本效益,NeuroSAFE与CLM等量使用时NeuroSAFE最优,若NeuroSAFE使用比例少超8%则CLM最优。

要点

  • RP中IOMA(NeuroSAFE或CLM)相比非IOMA策略具成本效益。
  • NeuroSAFE与CLM等量使用时NeuroSAFE最具成本效益。
  • NeuroSAFE使用比例少超8%时CLM最具成本效益。

核心结论

  • 根治性前列腺切除术中实施切缘评估是具成本效益的干预。
  • 选择NeuroSAFE或CLM应依据手术量和可用能力,NeuroSAFE劳动密集性可能限制其使用并降低相对CLM的成本效益。

研究设计与样本

  • 决策分析模型评估NeuroSAFE和CLM(使用Histolog®扫描仪)相比双侧、单侧和非神经保留手术的健康结局与成本。
  • 结局以质量调整生命年(QALY)计算,成本效益阈值为每QALY €50 000。

主要发现

  • NeuroSAFE和CLM相比非IOMA策略均具成本效益。
  • NeuroSAFE与CLM等量使用时NeuroSAFE最具成本效益;若NeuroSAFE使用比例少超8%则CLM最具成本效益。
  • 敏感性分析强调阳性手术切缘(PSM)对成本效益的影响。
  • 年RP量>160例的医院中CLM每例成本低于NeuroSAFE。

关键数值与推荐

  • 成本效益阈值为每QALY €50 000。
  • NeuroSAFE使用比例较CLM少超8%时,CLM最具成本效益。
  • 医院年RP量>160例时,CLM每例成本低于NeuroSAFE。

临床怎么用

  • RP中可考虑采用IOMA策略以平衡神经保留与切缘控制。
  • 选择NeuroSAFE或CLM需结合医院手术量和可用能力。
  • 高手术量医院中CLM可能因每例成本更低而更具优势。

局限性

  • 模型结果依赖假设参数,敏感性分析提示PSM影响成本效益。
  • NeuroSAFE劳动密集性可能限制其实际应用并影响成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether current intraoperative margin assessment (IOMA) techniques (such as Neurovascular Structure Adjacent Frozen-section Examination [NeuroSAFE] or confocal laser microscopy [CLM]) used during radical prostatectomy (RP) to enhance nerve-sparing surgery (NSS) while reducing positive surgical margins (PSMs) justify their extra costs, this study assessed their cost-effectiveness. METHODS: A decision analytical model assessed health outcomes and costs associated with NeuroSAFE and CLM (using the Histolog® Scanner) compared to bilateral, unilateral, and non-NSS. Outcomes were calculated in quality-adjusted life years (QALYs), with a cost-effectiveness threshold of €50 000 per QALY. NSS reduced erectile dysfunction and incontinence probabilities. However, when extraprostatic extension was present but not identified pre- or intraoperatively, NSS resulted in a PSM, increasing the risk of biochemical recurrence (BCR) and development of metastases. RESULTS: The NeuroSAFE and CLM were cost-effective strategies compared to non-IOMA strategies. NeuroSAFE was most cost-effective if NeuroSAFE and CLM were used in an equal number of patients. However, if NeuroSAFE was used in >8% fewer patients compared to CLM, CLM was most cost-effective. Sensitivity analyses highlighted the impact of PSMs on cost-effectiveness. In hospitals with higher RP volumes (>160 per year), CLM had lower costs per procedure than NeuroSAFE. CONCLUSIONS: Intraoperative margin assessment during RP is a cost-effective intervention. The choice to implement NeuroSAFE or CLM should be guided by both surgical volume and available capacity, as the more labour-intensive nature of NeuroSAFE may limit its use and reduces its cost-effectiveness compared with CLM.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. van Drumpt J, Govers T, Almeida-Magana R, et al. The cost-effectiveness of intraoperative margin assessment strategies during radical prostatectomy. BJU Int. 2026. PMID: 41568609. doi:10.1111/bju.70121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。